nucleosid
analog
play
critic
role
antivir
therapi
begin
approv
first
antivir
drug
idoxuridin
treatment
herp
simplex
viru
hsv
sinc
nucleosid
analog
approv
treatment
infect
caus
sever
dna
rna
virus
respons
signific
morbid
mortal
includ
human
immunodefici
viru
hiv
hepat
b
viru
hepat
c
viru
hcv
varicellazost
viru
human
cytomegaloviru
antivir
mechan
compound
requir
metabol
intracellular
kinas
correspond
serv
competit
substrat
incorpor
viral
genom
virusencod
polymeras
genom
incorpor
result
cessat
andor
perturb
genom
replic
andor
gene
express
sinc
phosphoryl
ribonucleosid
analog
mimic
natur
ribonucleotid
may
also
incorpor
human
rna
mitochondri
dnadepend
rna
polymeras
polrmt
nuclear
rna
polymeras
pol
ii
iii
result
undesir
side
effect
develop
sever
ribonucleosid
analog
stop
result
toxic
observ
clinic
trial
prodrug
investig
treatment
hcv
halt
phase
ii
clinic
trial
due
cardiac
kidney
toxic
balapiravir
prodrug
investig
treatment
hcv
stop
phase
ii
clinic
trial
due
hematolog
toxic
case
later
studi
suggest
caus
observ
toxic
mitochondri
dysfunct
zidovudin
first
approv
antiretrovir
hiv
treatment
shown
doselimit
toxic
result
deplet
mitochondri
dna
mtdna
examin
earli
drug
develop
process
potenti
nucleosid
analog
caus
mitochondri
toxic
seri
vitro
assay
develop
character
effect
compound
mitochondri
dna
copi
number
mitochondri
function
key
among
measur
mtdna
level
lactat
product
mitochondri
protein
express
nhc
ribonucleosid
analog
current
latestag
preclin
develop
nhc
shown
broadspectrum
antivir
activ
virus
togavirida
flavivirida
coronavirida
pneumovirida
orthomyxovirida
famili
shown
nhc
serv
competit
altern
substrat
incorpor
viral
rna
upon
incorpor
nhc
inhibit
viral
rna
genom
replic
either
disrupt
secondari
structur
genom
promot
region
thu
inhibit
replic
viru
introduct
mutat
viral
rna
genom
lead
error
catastroph
given
compound
ribonucleosid
analog
potenti
interf
mitochondri
function
seri
experi
design
evalu
effect
prolong
exposur
nhc
mitochondri
death
mitochondri
dysfunct
vitro
conduct
prior
conduct
experi
mitochondri
function
cytotox
concentr
nhc
determin
cell
line
use
studi
result
assay
summar
tabl
tabl
supplement
materi
valu
human
hepat
origin
cell
line
measur
cell
grown
glucosecontain
media
glucosefre
media
cell
grown
presenc
glucos
subject
crabtre
effect
wherebi
abl
produc
nearli
atp
glycolysi
even
though
cell
possess
function
mitochondria
furthermor
shown
cell
suscept
mitochondri
toxin
glucos
replac
galactos
incub
media
sidebysid
experi
valu
nhc
similar
cell
incub
glucos
cell
incub
galactos
instead
glucos
measur
nhc
impair
mitochondri
function
cell
line
among
test
cell
line
differ
tissu
speci
origin
tlymphoblastoid
origin
cem
cell
line
suscept
nhc
treatment
valu
lower
cell
line
test
see
tabl
therefor
cem
cell
line
chosen
evalu
potenti
nhc
caus
mitochondri
toxic
addit
cell
line
also
chosen
sinc
cell
tradit
use
evalu
mitochondri
toxic
demonstr
util
ribonucleosid
analog
must
convert
metabolit
util
substrat
rna
polymeras
incorpor
rna
confirm
nhc
convert
form
nhctp
cem
cell
incub
nhc
intracellular
level
nhctp
quantifi
liquid
chromatographytandem
mass
spectrometri
lcmsm
cell
treat
nhc
intracellular
nhctp
level
reach
maximum
concentr
cell
incub
fig
remain
stabl
h
presenc
drug
media
level
appear
higher
previous
report
valu
cell
determin
incub
nhc
cem
cell
treat
nhc
intracellular
level
nhctp
reach
maximum
cell
incub
fig
cell
treat
nhc
intracellular
level
nhctp
reach
maximum
concentr
cell
incub
fig
experi
confirm
nhc
effici
convert
metabolit
test
cell
nonradioact
primer
extens
assay
use
determin
whether
nhctp
incorpor
rna
polrmt
cytidin
analog
incorpor
effici
ribonucleosid
analog
usual
compar
natur
ribonucleosid
howev
case
ctp
analog
ctp
incorpor
much
effici
polrmt
ctp
analog
make
difficult
directli
compar
incorpor
effici
condit
facilit
measur
use
intermediari
singl
nucleotid
incorpor
primer
extens
assay
determin
polrmt
favor
substrat
nhctp
discrimin
valu
fig
previous
determin
polrmt
favor
ctp
discrimin
factor
extrapol
polrmt
favor
ctp
substrat
nhctp
factor
approxim
valu
suggest
nhctp
rel
effici
substrat
polrmt
determin
nhctp
caus
immedi
chaintermin
upon
incorpor
nascent
chain
rna
altern
assay
multipl
nucleotid
could
incorpor
fig
shown
fig
nhctp
incorpor
canalog
posit
nhctp
incorpor
ganalog
form
band
uanalog
posit
condit
compet
natur
gtp
utp
present
partial
chain
termin
occur
multipl
site
downstream
incorpor
nhctp
demonstr
accumul
unextend
band
posit
sinc
nhctp
substrat
polrmt
nhcmodifi
rna
may
differ
translat
properti
import
understand
polrmtmedi
protein
express
select
affect
cell
incub
nhc
effect
nhc
express
mitochondri
dnaencod
protein
cytochrom
c
oxidas
subunit
compar
effect
express
nuclear
dnaencod
protein
succin
dehydrogenas
sdha
cell
use
enzymelink
immunosorb
assay
elisa
base
quantit
assay
cell
chosen
shown
highli
sensit
mitochondri
toxin
assay
therefor
prefer
analysi
result
assay
shown
fig
tabl
cell
incub
increas
concentr
nhc
measur
inhibitori
concentr
valu
protein
express
lower
rel
sdha
protein
express
suggest
nhc
slightli
stronger
neg
effect
mitochondri
mrna
transcript
andor
translat
comparison
chloramphenicol
use
posit
control
exhibit
stronger
effect
mitochondri
protein
express
valu
protein
inhibit
lower
compar
sdha
protein
see
tabl
similarli
dideoxycytidin
ddc
show
select
inhibit
express
ratio
mitochondri
toxic
exhibit
decreas
mitochondri
number
per
cell
decreas
function
exist
mitochondria
decreas
function
activ
mitochondria
result
less
product
atp
mitochondria
even
mitochondri
number
chang
glucosecontain
cultur
medium
condit
decreas
mitochondri
number
mitochondri
function
affect
cell
put
addit
demand
atp
product
mitochondrionindepend
anaerob
glycolysi
regist
increas
lactat
product
determin
whether
mechan
involv
ie
decreas
mitochondri
quantiti
decreas
mitochondri
function
due
decreas
mitochondri
protein
quantiti
protein
function
effect
longterm
incub
nhc
mitochondri
number
lactat
product
treat
cell
investig
measur
longterm
effect
exposur
nhc
cell
incub
nhc
day
cem
cell
incub
nhc
day
concentr
select
near
concentr
correspond
cell
line
higher
treatment
concentr
could
test
sinc
enough
cell
surviv
perform
assay
day
treatment
mtdna
copi
number
cell
lactat
level
cell
cultur
media
measur
rel
mocktreat
cell
ddc
known
inhibitor
dna
polymeras
ethidium
bromid
etbr
mitochondri
replic
inhibitor
use
posit
control
data
experi
summar
tabl
signific
differ
rel
mtdna
level
cell
treat
nhc
day
either
concentr
treatment
level
rel
mtdna
cell
compar
mocktreat
control
treatment
rel
level
mtdna
control
differ
statist
signific
p
parallel
treatment
posit
control
ddc
etbr
result
mtdna
decreas
respect
compar
mocktreat
control
lactat
level
nhctreat
cell
rel
mockcontrol
cell
treat
treat
indic
signific
increas
lactat
product
day
treatment
either
concentr
treatment
posit
control
ddc
etbr
result
extracellular
lactat
increas
respect
cem
cell
treat
nhc
rel
mtdna
measur
respect
compar
mocktreat
control
although
differ
rel
mtdna
level
control
statist
signific
p
like
meaning
particularli
consid
addit
decreas
observ
higher
treatment
concentr
comparison
cem
cell
treat
posit
control
rel
mtdna
level
decreas
incub
ddc
cell
incub
etbr
lactat
level
cem
cell
incub
nhc
increas
slightli
rel
mock
control
increas
incub
nhc
cem
cell
treat
posit
control
lactat
level
treatment
ddc
treatment
etbr
ribonucleosid
analog
current
late
stage
preclin
develop
broadspectrum
antivir
agent
sinc
number
nucleosid
analog
halt
differ
stage
develop
due
mitochondri
toxic
conduct
investig
determin
potenti
nhc
interact
cellular
process
could
lead
mitochondri
toxic
dysfunct
previous
report
studi
conclud
nhc
caus
mitochondri
toxic
base
observ
nhc
effect
mitochondri
dna
rna
level
treatment
report
comprehens
seri
experi
design
thoroughli
investig
potenti
nhc
caus
mitochondri
toxic
longer
treatment
period
higher
concentr
cell
line
sensit
cytotox
nhc
result
indic
mitochondri
impair
nhc
substanti
contribut
observ
cytotox
glucosefre
media
mitochondri
toxic
signific
impact
due
crabtre
effect
differ
observ
cytotox
valu
compar
observ
glucosecontain
media
inhibit
dnapolymeras
tabl
incorpor
cellular
rna
could
caus
observ
cytotox
incorpor
nhc
residu
pol
ii
rna
could
suggest
elev
level
mutat
found
pol
iitranscrib
mrna
presenc
nhc
cellular
rna
pol
ii
possess
safeguard
activ
misincorpor
abl
excis
misincorpor
nucleotid
howev
polrmt
lack
abil
given
nhc
effici
substrat
polrmt
potenti
disrupt
vital
mitochondri
function
respirationdepend
atp
product
polrmtsynthes
short
rna
serv
primer
mitochondri
dna
synthesi
dna
polymeras
inhibit
mitochondri
rna
synthesi
result
nhc
incorpor
could
potenti
affect
replic
mtdna
nhc
caus
partial
delay
chain
termin
incorpor
polrmt
could
potenti
caus
toxic
due
decreas
quantiti
mitochondri
rna
hand
high
concentr
compet
ctp
utp
gtp
present
cell
physiolog
concentr
rang
may
reduc
likelihood
nhc
misincorpor
level
would
affect
rna
synthesi
stuyver
et
al
show
mitochondri
mrna
level
unchang
cell
incub
nhc
day
suggest
nhctp
incorpor
frequenc
requir
reduc
mitochondri
rna
synthesi
nhc
incorpor
polrmt
cytidin
uridin
analog
lesser
extent
guanosin
analog
incorpor
nhc
cytidin
uridin
analog
may
result
product
mutagen
mitochondri
mrna
either
translat
less
effici
translat
mutat
potenti
lessfunct
protein
fact
mutat
nuclear
mitochondri
mrna
observ
tissu
cultur
cell
treat
nhc
day
howev
increas
frequenc
mitochondri
nuclear
mrna
mutat
ferret
given
seven
dose
nhc
twice
daili
bid
mgkgday
despit
fact
plasma
level
nhc
expect
time
throughout
treatment
cours
shown
nhc
effici
anabol
triphosph
form
primari
hepatocyt
anim
organ
vivo
decreas
quantiti
mitochondri
protein
potenti
decreas
function
activ
mitochondri
protein
may
result
less
product
atp
mitochondria
even
mitochondri
number
chang
happen
affect
cell
switch
atp
product
mitochondrionindepend
anaerob
glycolysi
regist
increas
lactat
product
although
concentr
differ
mitochondri
nuclear
protein
express
see
fig
differ
translat
decreas
number
mitochondria
per
cell
measur
mtdnacel
increas
lactat
product
long
incub
nhc
cell
treat
nhc
day
signific
differ
mtdna
level
extracellular
lactat
level
cem
cell
rel
mtdna
level
reduc
concentr
nhc
extracellular
lactat
level
also
increas
less
cell
incub
lower
concentr
chang
extracellular
lactat
level
cell
incub
higher
concentr
nhc
previous
suggest
increas
extracellular
lactat
less
biolog
relev
regist
effect
cem
cell
like
indic
mitochondri
toxic
sinc
dose
respons
rel
mtdna
deplet
increas
extracellular
lactat
higher
nhc
concentr
suggest
spare
capac
mitochondria
toler
reduct
respiratori
chain
complex
activ
impact
atp
synthesi
mitochondri
respir
shown
activ
cytochrom
c
oxidas
protein
mitochondri
respiratori
chain
complex
mitochondria
isol
rat
muscl
brain
could
inhibit
kcn
without
major
chang
mitochondri
respir
atp
synthesi
also
shown
cell
contain
transplant
mtdna
contain
stop
codon
gene
mtdna
activ
still
measur
rel
cell
contain
nonmut
mtdna
theoriz
exist
excess
respiratori
chain
complex
allow
threshold
effect
provid
mitochondria
spare
amount
enzym
necessari
function
even
enzym
diminish
point
confirm
excess
capac
cytochrom
c
oxidas
respir
mitochondria
suggest
could
mechan
threshold
effect
nhc
inhibit
express
mitochondri
dna
encod
protein
lower
concentr
compar
express
nuclear
dna
encod
sdha
protein
cell
protein
express
lower
sdha
protein
express
suggest
nhc
stronger
impact
protein
express
possibl
due
absenc
proofread
activ
polrmt
littl
discuss
relev
differ
public
hand
measur
nhc
cell
base
quantit
intracellular
atp
level
determin
see
tabl
fig
suggest
treatment
nhc
inhibit
mitochondri
function
threshold
level
necessari
affect
atp
synthesi
current
vivo
treatment
data
nhc
also
indic
signific
toler
nhc
anim
least
shortdur
treatment
report
nhc
well
toler
mice
guinea
pig
given
bid
oral
dose
mgkgday
day
mice
day
guinea
pig
nhc
also
well
toler
ferret
given
bid
oral
dose
nhc
mgkgday
day
anoth
group
report
six
daili
dose
intraperiton
ip
inject
nhc
mgkgday
also
well
toler
mice
though
elev
ip
dose
nhc
mgkgday
appar
caus
weight
loss
revers
immedi
end
dose
quick
revers
would
impli
perman
damag
mitochondri
function
organ
ester
prodrug
design
current
develop
treatment
broad
rang
rna
viru
infect
initi
focu
treatment
encephalit
alphaviru
infect
influenza
although
extens
work
anim
model
infect
indic
durat
treatment
short
like
three
day
dose
everi
effort
made
determin
whether
mitochondri
toxic
could
still
impact
util
end
studi
report
extend
day
use
high
concentr
nhc
result
strongli
suggest
mitochondri
toxic
dose
durat
treatment
limit
issu
chronictox
studi
day
way
rat
dog
everi
effort
made
monitor
toxic
aris
mitochondri
dysfunct
nhc
prepar
previous
describ
ddc
purchas
tokyo
chemic
industri
america
boston
ethidium
bromid
sigmaaldrich
st
loui
mo
chemic
commerci
sourc
cell
atcc
use
cytotox
assay
maintain
three
passag
glucosefre
rpmi
media
vwr
intern
suwane
ga
supplement
mm
galactos
sigmaaldrich
fetal
bovin
serum
fb
atlanta
biolog
floweri
branch
ga
mm
lglutamin
vwr
penicillinstreptomycin
vwr
cell
use
assay
maintain
glucosecontain
rpmi
vwr
supplement
fb
mm
lglutamin
penicillinstreptomycin
cem
cell
atcc
maintain
rpmi
media
supplement
fb
mm
lglutamin
penicillinstreptomycin
cell
atcc
incub
ham
complet
medium
thermo
fisher
scientif
waltham
contain
fb
hi
mm
lglutamin
penicillinstreptomycin
cell
divid
two
part
first
resuspend
seed
glucosefre
media
second
resuspend
glucosecontain
media
cell
cell
plate
plate
cell
per
well
follow
incub
overnight
attach
addit
drug
cem
cell
plate
cell
per
well
immedi
drug
addit
cell
incub
presenc
increas
concentr
nhc
day
atmospher
cell
viabil
measur
intracellular
atp
level
determin
use
celltiterglo
cell
viabil
assay
kit
promega
madison
wi
accord
manufactur
instruct
cell
cell
cem
cell
incub
nhc
previous
describ
briefli
cell
incub
nhc
h
wash
phosphatebuff
salin
pb
extract
methanol
water
cell
incub
nhc
h
wash
pb
extract
acetonitril
water
extract
centrifug
store
analysi
lcmsm
cem
cell
incub
nhc
h
cell
centrifug
wash
pb
cell
pellet
extract
methanol
water
extract
clarifi
centrifug
store
analysi
metabolit
nhc
nhctp
quantit
lcmsm
agil
system
agil
technolog
santa
clara
ca
equip
sequant
zicphil
column
milliporesigma
burlington
mobil
phase
consist
mm
ammonium
bicarbon
water
ph
acetonitril
use
mobil
phase
b
mass
spectrometri
analysi
perform
qtrap
mass
spectromet
sciex
framingham
multiplereactionmonitor
mode
data
analysi
perform
use
analyst
softwar
sciex
framingham
polrmt
primer
extens
reaction
perform
previous
describ
briefli
nm
concentr
fluoresc
label
rna
primer
anneal
dna
templat
primertempl
pt
sequenc
shown
top
correspond
figur
nm
polrmt
atp
increas
concentr
nhctp
incub
min
sampl
separ
use
denatur
polyacrylamid
gel
electrophoresi
page
gel
scan
use
odyssey
infrar
imag
system
licor
bioscienc
lincoln
ne
proper
rna
band
quantifi
use
imag
studio
lite
softwar
licor
bioscienc
cell
treat
test
compound
increas
concentr
day
analyz
previous
describ
colorimetr
mitobiogenesi
incel
elisa
kit
abcam
cambridg
unit
kingdom
briefli
cell
plate
plate
densiti
cellswel
ham
complet
medium
day
incub
drug
cellular
level
mitochondri
dnaencod
protein
nuclear
dnaencod
protein
sdha
analyz
use
assay
kit
accord
manufactur
protocol
colorimetr
analysi
perform
use
spectramax
spectrophotomet
molecular
devic
san
jose
ca
chloramphenicol
ddc
use
posit
control
cell
treat
sodium
pyruvatecontain
dulbecco
modifi
eagl
medium
supplement
dialyz
fb
life
technolog
uridin
alfa
aesar
haverhil
lglutamin
penicillinstreptomycin
cell
seed
cellswel
ml
media
per
well
plate
day
addit
test
compound
cem
cell
treat
rpmi
media
supplement
dialyz
fb
mm
sodium
pyruv
life
technolog
uridin
alfa
aesar
lglutamin
penicillinstreptomycin
cem
cell
seed
cellsml
ml
media
per
well
plate
day
addit
drug
cell
cultur
continu
day
presenc
compound
cell
medium
chang
day
day
media
fresh
drug
cem
cell
passag
dilut
day
media
fresh
drug
day
cellfre
cultur
medium
collect
cell
collect
count
use
dispos
hemocytomet
incyto
covington
ga
experi
repeat
three
time
repeat
initi
differ
day
lactat
concentr
cellfre
medium
measur
use
enzychrom
llactat
assay
kit
bioassay
system
hayward
ca
briefli
sampl
dilut
water
lactat
concentr
measur
accord
manufactur
instruct
lactat
concentr
express
percentag
mocktreat
control
effect
drug
mitochondri
dna
quantiti
per
cell
measur
compar
rel
mitochondri
genom
copi
number
mtdna
copi
number
divid
nuclear
dna
copi
number
cell
treat
drug
versu
mocktreat
cell
nuclear
dna
target
sequenc
use
correspond
gene
mitochondri
target
sequenc
use
correspond
mitochondri
dna
nucleotid
posit
primer
taqman
probe
eurofin
mwg
operon
louisvil
ky
use
realtim
pcr
order
follow
primer
probe
use
quantif
nuclear
dna
gene
sens
primer
antisens
primer
probe
fam
caccacggccgagcggga
bhq
primer
probe
quantif
mtdna
forward
primer
revers
primer
mitoprob
fam
ctagtctttgccgcctgcgaagca
bhq
cell
collect
day
drug
treatment
pellet
centrifug
g
min
cell
pellet
resuspend
pb
total
dna
isol
use
dneasi
tissu
kit
qiagen
hilden
germani
cellular
dna
mocktreat
cell
serial
dilut
use
gener
correspond
standard
curv
determin
rel
copi
number
gene
target
qpcr
sampl
perform
triplic
realtim
pcr
system
appli
biosystem
foster
citi
ca
total
reaction
volum
contain
pcr
mix
life
technolog
carlsbad
ca
nm
probe
nuclear
dna
mitoprob
mtdna
nm
sens
antisens
primer
nuclear
dna
primer
mtdna
purifi
serial
dilut
dna
sampl
mitochondri
cellular
genom
copi
number
calcul
base
standard
curv
rel
mitochondri
copi
numbercel
calcul
divid
measur
mitochondri
copi
number
copi
number
gene
chang
mitochondri
copi
numbercel
express
percentag
mocktreat
control
